Research into psychedelics is increasingly revealing that these purportedly dangerous drugs may have potent mental health benefits. While modern antidepressants work by influencing the levels of hormones such as serotonin in the brain, psychedelics seem to deliver their benefits by influencing the mind and perception.
Their unique effects allow psychedelics to deliver long-term benefits against a myriad of mental disorders, with minimal side effects.
Clinical studies have found that psychedelics, including psilocybin, can treat conditions such as major depressive disorder when conventional treatments have failed. A recent study looking at the potential benefits and risks of microdosing psychedelics has found that there may be an association between microdosing and increased authenticity.
Microdosing refers to the practice of taking tiny doses of psychedelics while remaining within the therapeutic dose to avoid experiencing any mind-bending effects. It has gained popularity in recent years as more people turn away from conventional treatments in favor of psychedelics to treat conditions like anxiety and depression.
According to the recent study, microdosing psychedelics may result in a heightened feeling of authenticity in users. Researchers recruited 18 participants and collected data over the course of a month during 192 observation sessions. The individuals were asked to provide assessments of their state of authenticity on nonmicrodosing and microdosing days.
The research team also recorded the activities the participants engaged in over the study period and the level of satisfaction they drew from these activities.
Mixed-effects models were used to analyze the data after emotional states, trait authenticity and demographic information were used as control variables. The researchers measured state authenticity using the Real-Self Overlap Scale while an indicator variable was used to assess the microdosing. A mixed-effects model was then used to test the hypotheses that microdosing psychedelics was somehow associated with increased authenticity.
The researchers found that microdosing resulted in elevated levels of the of state authenticity on the day of dosing and the day after. They also discovered that the 18 study participants found more satisfaction in daily activities after microdosing psychedelics and were more likely to cook, read write and engage in chores.
The findings suggest that microdosing psychedelics may make users feel more authentic and increase the satisfaction they derive from daily activities. The researchers behind the study indicate that microdosing may help individuals feel more connected to their emotions and thoughts and make it easier for them to act in ways that genuinely mirror their internal desires and values.
While these studies point to the potential benefits of microdosing, it is important to keep in mind that these psychedelics could pose some risks to users, which is why a lot of companies such as atai Life Sciences N.V. (NASDAQ: ATAI) are focusing their drug-development efforts on formulations that require to be used in a clinical setting.
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.